Fig. 5.
(A) Comparison of overall survival time according to percentage activated CTLs. (B) Comparison of overall survival time according to percentage activated CTLs combined with ALK status. (C) Comparison of progression-free survival time according to percentage activated CTLs combined with ALK status.